⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
BTAI News
BioXcel Therapeutics, Inc. Common Stock
BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions
globenewswire.com
BTAI
Mosaic Therapeutics nomme Vince O’Neill au poste de directeur de la R&D
businesswire.com
BTAI
SNY
GSK
BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI® in the At-Home Setting
globenewswire.com
BTAI
Form 8-K
sec.gov
BTAI
Mosaic Therapeutics appoints Dr Vince O'Neill, MD, as Head of R&D
businesswire.com
BTAI
MRNA
Form 8-K
sec.gov
BTAI
BioXcel Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results as Company Prepares for Potential IGALMI® Approval in Outpatient Setting
globenewswire.com
BTAI
Levi & Korsinsky, LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of BioXcel Therapeutics, Inc.
globenewswire.com
BTAI
Exosome Research Market Analysis, Opportunity Forecasts Report 2026-2035
globenewswire.com
CRBP
BTAI
Form 8-K
sec.gov
BTAI